Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Albuterol; Magnesium Sulfate

Criteria

Inclusion Criteria:

• Patients age ≥ seven years

• Previous diagnosis of asthma or previous episode of wheezing treated with beta-agonist medication

• Able to complete bedside spirometry

• FEV1 < 70% predicted

Exclusion Criteria:

• Known allergy to magnesium sulfate

• Known contra-indication to albuterol

• Respiratory distress occurring as a result of bedside spirometry

• History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease

• Pregnancy

• Use of oral steroid medication within 72 hours of presentation

• Radiographic evidence of pneumonia at presentation

• Intubation during the current encounter prior to study enrollment

• Administration of intravenous magnesium sulfate prior to study enrollment

• Prior participation in this study